Will Johnson & Johnson Go Into Generics?
Make a commentBy Ed Silverman // June 26th, 2008 // 7:50 am
Hard to say. But at the very end of a recent - and, unfortunately, not very revealing - interview at The Wharton School, Bill Weldon hints that generics aren’t being ruled out. Sure, the J&J ceo talks about being a research company and brags that pharma is about 40 percent of revenue these days. But his pharma division has issues with restrictions on Procrit and generating interest in its Invega follow-up to the Risperdal antipsychotic. Here’s the transcript…